Lung viral infection modelling in a bioengineered whole-organ

• Published in: Biomaterials Vol. 301; p. 122203
• Main Authors: Tommasini, Fabio, Benoist, Thomas, Shibuya, Soichi, Woodall, Maximillian N.J., Naldi, Eleonora, Palor, Machaela, Orr, Jessica C., Giobbe, Giovanni Giuseppe, Maughan, Elizabeth F., Saleh, Tarek, Gjinovci, Asllan, Hutchinson, J. Ciaran, Arthurs, Owen J., Janes, Sam M., Elvassore, Nicola, Hynds, Robert E., Smith, Claire M., Michielin, Federica, Pellegata, Alessandro Filippo, De Coppi, Paolo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.10.2023; Published by Elsevier Ltd
• Subjects: Animals; COVID-19; Decellularization; Epithelial Cells; Epithelialization; Humans; Lung; Lung tissue engineering; Neutrophils; Pneumonia; Rats; RSV; Tissue Scaffolds - chemistry; Viral infection; Virus Diseases; Lung tissue engineering; Epithelialization; RSV; Viral infection; Decellularization; Neutrophils
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2023.122203

Lung infections are one of the leading causes of death worldwide, and this situation has been exacerbated by the emergence of COVID-19. Pre-clinical modelling of viral infections has relied on cell cultures that lack 3D structure and the context of lung extracellular matrices. Here, we propose a bioreactor-based, whole-organ lung model of viral infection. The bioreactor takes advantage of an automated system to achieve efficient decellularization of a whole rat lung, and recellularization of the scaffold using primary human bronchial cells. Automatization allowed for the dynamic culture of airway epithelial cells in a breathing-mimicking setup that led to an even distribution of lung epithelial cells throughout the distal regions. In the sealed bioreactor system, we demonstrate proof-of-concept for viral infection within the epithelialized lung by infecting primary human airway epithelial cells and subsequently injecting neutrophils. Moreover, to assess the possibility of drug screening in this model, we demonstrate the efficacy of the broad-spectrum antiviral remdesivir. This whole-organ scale lung infection model represents a step towards modelling viral infection of human cells in a 3D context, providing a powerful tool to investigate the mechanisms of the early stages of pathogenic infections and the development of effective treatment strategies for respiratory diseases.